Sunitinib-induced hypothyroidism.
- Author:
Yun Jae CHUNG
1
Author Information
1. Division of Endocrinology, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
- Publication Type:Editorial
- Keywords:
Sunitinib;
Tyrosine kinase inhibitor;
Hypothyroidism
- MeSH:
Breast Neoplasms;
Carcinoma, Non-Small-Cell Lung;
Carcinoma, Renal Cell;
Colonic Neoplasms;
Gastrointestinal Stromal Tumors;
Humans;
Hypothyroidism;
Incidence;
Indoles;
Protein-Tyrosine Kinases;
Pyrroles;
Thyroid Gland
- From:Korean Journal of Medicine
2010;79(5):506-508
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor that is effective for advanced renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor. Currently, sunitinib is being investigated in multiple other tumor types including non-small cell lung cancer, breast cancer, colon cancer, and endocrine tumors. Recent studies have shown that sunitinib induces thyroid dysfunction, mainly hypothyroidism during treatment. The incidence of sunitinib-induced hypothyroidism has been reported to be 36~85%. Although several hypotheses have been suggested, the mechanisms by which sunitinib induces hypothyroidism are not clear. As considered the fairly high incidence of sunitinib-induced hypothyroidism, thyroid function should be regularly monitored in all patients treated with sunitinib.
